Vaccine developer Pfizer announces that lab studies have concluded that the joint Pfizer–BioNTech vaccine remains effective against mutation variants of the SARS-CoV-2 virus, including Variant of Concern 202012/01 and the 501.V2 variant. (BBC) Tozinameran, Variants of SARS-CoV-2COVID-19 pandemic link embed save